logo
Plus   Neg
Share
Email

McCormick Reaffirms FY19 Outlook - Quick Facts

While reporting financial results for the first quarter of fiscal 2019 on Tuesday, McCormick & Co., Inc. (MKC) reaffirmed its earnings per share and sales outlook for the full year.

The company said it expects another year of strong performance driven by its broad and advantaged flavor portfolio, effective growth strategies and focus on profit realization.

For fiscal 2019, the company continues to project earnings in the range of $5.09 to $5.19 per share and adjusted earnings in the range of $5.17 to $5.27 per share on sales growth of 1 to 3 percent, which in constant currency is a 3 to 5 percent projected growth rate.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.22 per share on sales growth of 1.7 percent to $5.50 billion for the year. Analysts' estimates typically exclude special items.

The company also projects another year of strong cash flow, with plans to return a significant portion to McCormick's shareholders through dividends and to pay down debt.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
NBCUniversal unveiled Peacock, a free premium ad-supported streaming service with subscription tiers offering more than 600 movies and 400 series. Peacock will be available on April 15 for Comcast's Xfinity X1 and Flex customers and on July 15 for the rest of the country. NBC is offering Peacock... The number of Amazon Prime members in the U.S. is growing slowly, but steadily, a recent study has shown. According to the survey by the Consumer Intelligence Research Partners, LLC or CIRP, the number of Amazon Prime members in the U.S. is estimated to have risen to 112 million in December 2019 from just over 100 million in the same period of the prior year. Medical device manufacturer Cardinal Health will soon recall certain Level 3 surgical gowns or PreSource procedural packs that contain these gowns following warning that they may not be sterile, the U.S. Food and Drug Administration said in a statement. The health regulator said it is working with the company to find out the specific product lots that are impacted.
Follow RTT
>